INTRODUCTION
• Prostate cancer is diagnosed in 1.1 million men annually worldwide and > 300,000 men die from advanced forms of the disease each year. 1 • Despite initial surgical and/or radiological therapy and concomitant or subsequent use of androgen deprivation therapy (ADT), a nonsurvivable castration-resistant prostate cancer (CRPC) form emerges in 10%-20% of patients within 5 years. 2 • With continued ADT and as metastatic CRPC (mCRPC) progresses, many patients experience worsening symptoms resulting in progressive decline in health-related quality of life (HRQoL) and increase in pain status. 2 • Following approval of docetaxel + prednisone chemotherapy in 2004, there was little change in management until 2010. Since then, there has been an expansion of systemic treatment options, including abiraterone acetate + prednisone, enzalutamide, radium-223 dichloride, cabazitaxel, and sipuleucel-T, which prolong survival in patients with mCRPC and affect patients' HRQoL and pain.
• Comparing the impact of these therapies on HRQoL and pain is important for informing all stakeholders (including patients) of the balance between cancer control and toxicity.
OBJECTIVE
• To review patient-reported outcome (PRO) data reported in clinical trials of patients with mCRPC reported since 2010 in order to summarize the contemporary state of the science, identify gaps for future research, and facilitate informed decision making for patients.
METHODS
• We searched the US National Library of Medicine National Institutes of Health Medline database for randomized, controlled clinical trial articles published between Jan 2010 and Apr 2015 using the following Boolean search terms: (prostate cancer) AND (castration-resistant OR hormone-refractory OR androgen-independence) AND (randomised OR randomized).
• A second search was conducted as follows: (prostate cancer) AND (health-related quality of life OR HRQoL OR QoL) OR pain OR fatigue OR weight loss.
• Both searches were limited to articles in English and combined to create the full dataset of potentially eligible articles. • The title and abstract of each retrieved article were screened for relevance against predefined inclusion criteria: clinical studies in mCRPC with a sample size ≥ 50 patients.
• Full text articles were obtained and reviewed qualitatively by the authors for final inclusion and assessment based on endpoint reporting (i.e., time to deterioration in a PRO measure and proportion of patients with improvement in a PRO measure).
RESULTS
• Twenty of 26 publications describing 7 treatment regimens (10 clinical trials and 10 associated secondary analyses) met inclusion criteria and were critically appraised ( Table 1 ).
• Across the 10 clinical trials, 7 different patient-completed questionnaires measuring HRQoL and/or pain were used ( Table 1) , all of which have demonstrated reliability, have been subject to validation processes, are responsive to change in health state, and have well-established psychometric characteristics ( Table 2 ).
• The 2 most commonly used instruments to measure HRQoL and characterize pain were the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire (used in 5 of the trials), and the Brief Pain Inventory (BPI) Short Form (SF) (used in 4 of the trials).
Cytotoxic chemotherapy and immunotherapy
• The mitoxantrone, docetaxel, and cabazitaxel trials did not find statistically significant differences in HRQoL or pain scores vs comparison arms. [19] [20] [21] [22] • Sipuleucel-T was not associated with improvement in time to disease-related pain, although time to first use of opioid analgesics was delayed. 
CONCLUSIONS
• Our literature review found that contemporary, randomized, controlled clinical trials of mCRPC patients include HRQoL and pain measures that provide a more comprehensive understanding of the impact of new noncytotoxic treatments.
• While use of validated PRO questionnaires in clinical trials is encouraging, the endpoints and analytic methods deployed are inconsistent across studies.
• Nevertheless, results obtained from PRO tools used in the reviewed studies indicated that abiraterone acetate + prednisone, enzalutamide, radium-223 dichloride, and sipuleucel-T offer varying levels of HRQoL benefit and/or pain mitigation vs their respective comparators.
• As medical management of mCRPC transitions from a chronic disease paradigm to a palliative care approach, PROs that are subject to validation processes in the clinical practice setting will be required. 
Sipuleucel-T (sip-T)
IMPACT/D9901/D9902A 
EQ-5D
International, standardized, generic questionnaire for describing and valuing HRQoL. Population preference-based health state utility score (EQ-5D index) and patient's overall health state on a visual analog scale (VAS) are reliable and valid for assessing HRQoL in cancer patients. Higher scores represent better health states.
Worst pain 1 0-10
Least pain 1 0-10
Brief Pain Inventory (BPI) Short Form (SF)
Self-assessment tool measuring pain intensity and the amount pain interferes with activities of daily living rated using 11-point numerical scale of 0-10, with 10 being the worst level of pain or interference ("pain as bad as you can imagine") and 0 being no pain interference ("no pain").
f Each interference item is scored 0-10, with 0 representing "does not interfere" and 10 indicating "completely interferes." The most important difference between the longer and shorter versions of the BPI is that the latter uses a 24-hour recall period. 
FACT-P survival analysis
• Post-chemotherapy setting -In COU-AA-301, treatment with abiraterone acetate + prednisone reduced the risk of clinically meaningful deterioration in FACT-P total and prostate cancer subscale (PCS) scores by 39% relative to placebo + prednisone (Figure 1) . 4 -In AFFIRM, treatment with enzalutamide reduced the risk of clinically meaningful deterioration in FACT-P total score by 55% relative to placebo (Figure 1 ).
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• Similarly, both abiraterone acetate + prednisone and enzalutamide delayed median time to clinically meaningful deterioration in FACT-P total and PCS scores in the pre-chemotherapy setting (Figure 1) . 
Favors active treatment Favors comparator
Hazard ratio AA = abiraterone acetate; CI = confidence interval; DOC = docetaxel; ENZA = enzalutamide; HR = hazard ratio; NR = not reported; PBO = placebo; PRED = prednisone.
FACT-P responder analysis
• In the post-chemotherapy setting, COU-AA-301 and AFFIRM showed that the proportions of patients reporting clinically meaningful improvements in FACT-P total and PCS scores were higher with abiraterone acetate + prednisone (vs placebo + prednisone) and enzalutamide (vs placebo), respectively (Figure 2) . 4, 11 • Similar findings were observed in PREVAIL in favor of enzalutamide vs placebo for FACT-P total and PCS scores, 14 and in the ALSYMPCA study in favor of radium-223 dichloride vs placebo for FACT-P total score.
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Pain survival analysis
• Pain data were inconsistently reported.
• Therapy with enzalutamide reduced the risk of pain severity progression on the BPI-SF in the pre-chemotherapy setting by 40% (hazard ratio Abiraterone acetate + prednisone (pre-chemotherapy vs placebo + prednisone) and sipuleucel-T (post-chemotherapy vs control) did not extend pain progression-free survival on the BPI-SF. 6, 18 • Abiraterone acetate + prednisone reduced the risk of progression in BPI-SF pain at its worst in the post-chemotherapy setting (HR, 0.72; 95% CI, 0.56-0.92) 5 but not the pre-chemotherapy setting (HR, 0.85; 95% CI, 0.69-1.04), 6 whereas enzalutamide use in chemotherapy-naïve patients did reduce the median time to progression in pain at its worst (HR, 0.62; 95% CI, 0.53-0.74). 
